Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Aug;33(4):639-648.
doi: 10.1007/s40620-020-00773-6.

Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference

Andrew S Levey  1 , Kai-Uwe Eckardt  2 , Nijsje M Dorman  3 , Stacy L Christiansen  4 , Michael Cheung  5 , Michel Jadoul  6 , Wolfgang C Winkelmayer  7
Affiliations
Editorial

Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference

Andrew S Levey et al. J Nephrol. 2020 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

ASL declared having received research support from AstraZeneca, National Institute of Diabetes and Digestive and Kidney Diseases, and National Kidney Foundation. K-UE declared having received consultancy fees from Akebia, Bayer, and Genzyme; speaker honoraria from Bayer and Vifor; and research support from Amgen, AstraZeneca, Bayer, Fresenius Medical Care, and Genzyme. NMD declared having equity ownership/stock options from Eli Lilly & Co. MJ declared having received consultancy fees from Astellas, AstraZeneca, GSK, MSD, and Vifor Fresenius Medical Care Renal Pharma; speaker honoraria from Abbvie, Amgen, Menarini, MSD, and Vifor Fresenius Medical Care Renal Pharma; travel support from Amgen; and research support from Alexion, Amgen, Janssen-Cilag, Otsuka, and Roche. WCW declared having received consultancy fees from Akebia, AMAG, Amgen, AstraZeneca, Bayer, Daiichi-Sankyo, Relypsa, and ZS Pharma; speaker honoraria from FibroGen; and research support from National Institutes of Health. All the other authors declared no competing interests.

References

    1. Levey AS, Weiner DE. Editorial team. Staying put, but not standing still. Am J Kidney Dis. 2012;59:1–3. doi: 10.1053/j.ajkd.2011.11.004. - DOI - PubMed
    1. Kidney disease: International global outcomes. Consensus conference on nomenclature for kidney function and disease. Available at: https://kdigo.org/conferences/nomenclature/. Accessed April 24, 2020
    1. Plantinga LC, Boulware LE, Coresh J, et al. Patient awareness of chronic kidney disease: trends and predictors. Arch Intern Med. 2008;168:2268–2275. doi: 10.1001/archinte.168.20.2268. - DOI - PMC - PubMed
    1. James SL. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1789–1858. doi: 10.1016/S0140-6736(18)32279-7. - DOI - PMC - PubMed
    1. GBD Chronic Kidney Disease Collaboration Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395:709–733. doi: 10.1016/S0140-6736(20)30045-3. - DOI - PMC - PubMed

Publication types